<DOC>
	<DOCNO>NCT02690285</DOCNO>
	<brief_summary>The purpose study identify analyze frequency GSTZ1 haplotypes healthy adult population determine pharmacokinetics Dichloroacetate ( DCA ) metabolism base haplotype analysis . The DCA drug first target treatment Pyruvate Dehydrogenase Complex Deficiency ( PDCD ) . This pilot study , focus develop high throughput , sensitive accurate screen test determine glutathione transferase zeta 1 ( GSTZ1 ) haplotype status individual would treat DCA .</brief_summary>
	<brief_title>A Pilot Study Rapid Haplotyping Procedure Personalized Dosing Dichloroacetate ( DCA ) Healthy Volunteers</brief_title>
	<detailed_description>Pyruvate dehydrogenase complex ( PDC ) deficiency ( PDCD ) rare disease mitochondrial energy failure life expectancy affect child severely truncate . Treatment PDCD remain serious , unmet challenge . Dichloroacetate ( DCA ) represent first target therapy PDCD stimulate residual PDC activity . Cumulative experience DCA reveal dose accumulation subset population . This abated personalized dosing DCA , assign haplotype variation gene encode glutathione transferase zeta 1 ( GSTZ1 ) , biotransforms DCA glyoxylate . Haplotype variation GSTZ1 influence kinetics dynamic chronically administer DCA . A single dose DCA bioavailability approach unity widely distribute throughout body . The plasma half-life ( ½ ) ~1 hr drug-naïve subject . Gender influence DCA kinetics metabolism . The major route biotransformation via dehalogenation glyoxylate glutathione transferase zeta 1 ( GSTZ1 ) . DCA mechanism-based inhibitor GSTZ1 , repeat administration result increase plasma ½ decrease clearance .</detailed_description>
	<criteria>Healthy outline physical exam blood test Non smoker Can comprehend refuse sign inform consent form ; Febrile clinical sign infection ; Pregnant nursing ; In female , refuse use contraception avoid unprotected intercourse study ; Uncontrolled hypertension ( BPs &gt; 160 mmHg BPd &gt; 100 mmHg ) conventional medication ; Anemic ( hematocrit &lt; 35 % male ; &lt; 35 % female ; Serum creatinine ≥ 1.3 mg/dl , TSH &gt; 4.5 mIU/ml ; transaminase ( ALT AST ) &gt; 2 x ULN , total bilirubin &gt; 1.2 mg/dl fast glucose ≥ 110 mg/dl . History psychosis , seizures diabetes mellitus receive antipsychotic , antiepileptic blood glucoselowering medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>